Table 1.

Baseline characteristics.

Characteristic	All Patients (n = 200)	Docetaxel Alone (n = 69)	Docetaxel + Prednisone (n = 131)	P-value
Age (years)	68 (45 – 85)	68 (52 – 85)	69 (45 – 85)	0.45
Performance Status
0	75 (38%)	22 (32%)	53 (40%)	0.001
1 – 2	86 (43%)	21 (30%)	50 (50%)
Missing	39 (20%)	26 (38%)	13 (10%)
Hemoglobin (g/dL)	11.9 (7.7 – 15.9)	11.9 (7.7 – 15.9)	11.9 (8.1 – 15.3)	0.49
Creatinine (mg/dL)	0.9 (0.5 – 3.5)	1.0 (0.5 – 3.5)	0.9 (0.5 – 2.1)	0.08
Alkaline Phosphatase (IU/L)	137 (39 – 2109)	125 (44 – 684)	149 (39 – 2109)	0.22
PSA (ng/dL)	153 (1.2 – 5327)	131.1 (2.9 – 4861)	155.7 (1.2 – 5327)	0.96
Gleason score sum
6	13 (6%)	5 (7%)	8 (6%)	0.56
7	50 (25%)	17 (25%)	33 (25%)
8 – 10	116 (58%)	37 (54%)	79 (60%)
Missing	21 (10%)	10 (14%)	11 (8%)
Presence of visceral metastasis
Liver	30 (15%)	10 (14%)	20 (15%)	0.99
Lung	24 (12%)	6 (9%)	18 (14%)	0.36
Presence of pain	82 (41%)	26 (38%)	56 (43%)	0.55
Number of prior hormonal therapies	3 (1 – 5)	2 (1 – 5)	3 (1 – 5)	0.45
Prior Abiraterone – Prednisone	46 (23%)	9 (13%)	37 (28%)	0.02
Prior Ketoconazole – Hydrocortisone	77 (38%)	26 (38%)	51 (39%)	0.88
Prior Enzalutamide	14 (7%)	2 (3%)	12 (9%)	0.15

Data reported as median (range) or percentages. P-values for categorical variables are based on Fisher’s Exact test, and for continuous variables are based on Wilcoxon-Mann Whitney test.